Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Gregory Glance

Internal Medicine Asheville, NC Medical Doctor

NPI 1386610632 CMS profile 244098

4 Vanderbilt Park Dr Ste 100, Ste 200, Asheville, NC 28803

Open in the dashboard

General payments

$11,267

727 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Gregory Glance of Asheville, NC is reported in the CMS Open Payments database as having received $11,267 across 727 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $2,300 128
2022 General $2,636 161
2021 General $2,410 148
2020 General $1,600 112
2019 General $2,322 178

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gregory Glance
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Gregory Glance were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Gregory Glance Internal Medicine median Middle half National median
2019 $2,322 $159 $48–$570 $163
2020 $1,600 $119 $33–$402 $114
2021 $2,410 $135 $37–$521 $132
2022 $2,636 $141 $42–$496 $149
2023 $2,300 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Boehringer Ingelheim Pharmaceuticals, Inc. $1,193 81 payments
  2. Novo Nordisk Inc $1,164 81 payments
  3. Lilly USA, LLC $871 51 payments
  4. Pfizer Inc. $864 63 payments
  5. GlaxoSmithKline, LLC. $786 57 payments
  6. AbbVie, Inc. $692 47 payments
  7. Salix Pharmaceuticals, a division of Bausch Health US, LLC $677 40 payments
  8. Bayer HealthCare Pharmaceuticals Inc. $578 24 payments
  9. Janssen Pharmaceuticals, Inc $504 45 payments
  10. Amgen Inc. $481 31 payments
  11. Other $3,455 207 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $11,169 716 payments
  2. Education $98 11 payments
Products named General payments · program years 2019–2023
  1. JARDIANCE Diabetes $822 64 payments
  2. Ozempic $789 51 payments
  3. XIFAXAN $677 40 payments
  4. TRELEGY ELLIPTA $582 45 payments
  5. Kerendia $578 24 payments
  6. RYBELSUS $557 41 payments
  7. TRULICITY $505 30 payments
  8. JARDIANCE Diabetes $496 29 payments
  9. TRADJENTA $477 47 payments
  10. XARELTO $477 41 payments
  11. Other $10,399 708 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 157 drugs

Part D claims

12,574

Median for Internal Medicine: 777

Drug cost

$919,059

Median for Internal Medicine: $73,373

Branded share of claims

19.3%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 155 $193,588
Ozempic Semaglutide Brand 70 $100,621
Jardiance Empagliflozin Brand 70 $84,496
Xarelto Rivaroxaban Brand 61 $74,145
Trulicity Dulaglutide Brand 30 $42,092
Mounjaro Tirzepatide Brand 40 $41,142
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 29 $29,260
Linzess Linaclotide Brand 23 $28,513
Synjardy Xr Empagliflozin/Metformin Hcl Brand 25 $24,565
Premarin Estrogens, Conjugated Brand 49 $21,072

The 10 drugs with the highest cost, of 157 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 78 billing codes

Paid by Medicare

$257,563

Medicare's payments for the services billed

Medicare patients

645

Average age 77

Services billed

9,758

302 women, 343 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 38%
Chronic kidney disease 32%
Diabetes 24%
Depression 21%
Ischemic heart disease 20%
Atrial fibrillation 17%
Cancer 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

727 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record